semaj83/ctmatch_classification huggingface dataset:
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Foot Ulcer Diabetic Foot Skin Ulcer Diabetic Neuropathies Diagnosis of Type I or Type II diabetes mellitus and a glycohemoglobin A1c<12% Minimum of one neuropathic, diabetic ulcer meeting the following stage III or IV, located on the distal lower extremity, between 1 and 15 square centimeters No exposed bone at the ulcer site No osteomyelitis affecting the area of the ulcer unless receiving aggressive treatment with expectation of cure Adequate arterial circulation to the foot New ulcers must be meet the following full-thickness ulcer (Stage III or IV), located on feet or ankles, no exposed bone at the ulcer site, no osteomyelitis affecting the area of the ulcer unless receiving aggressive treatment with expectation of cure Recurrent ulcers must meet the following stage II, III or IV, no exposed bone at the ulcer site, no osteomyelitis affecting the area of the ulcer unless receiving aggressive treatment with expectation of cure Females must be postmenopausal, surgically incapable of childbearing, or using an acceptable method of birth control and have negative pregnancy test  Hypersensitivity to Gel or one of its components Presence of more than two full-thickness diabetic ulcers on either lower extremity presence of an active systemic or local cancer or tumor of any kind Use of topical antibiotics, antiseptics, enzymatic debriders, or any other agents on the selected ulcers, within the seven days preceding randomization Active rheumatic or collagen vascular disease or pre-existing conditions or diseases which may interfere with the evaluation of safety or efficacy of Regranex Systemic corticosteroid maintenance therapy, immunosuppressive or chemotherapeutic agents within 14 days prior to first study drug application or are likely to receive one of these therapies during study participation Radiation therapy that included the distal lower extremity, at any time in patient's life Charcot deformity (rocker bottom foot)
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 People with Type I or Type II Diabetes Years or Older
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 16.0-80.0,  Wounds Patients with a poorly healed wound, in which skin graft is clinically indicated  Skin infection Vital signs unstable
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Foot Ulcer Diabetes Provision of a written informed consent at the enrolment visit Men or women above 30 years of age Fertile women need to take contraceptives or have to be sterilised Diagnosed with any diabetes mellitus type 1 or type 2 Present foot ulcer with an ulcer duration <= 12 months  Intolerance to statins at any time in the past Unwillingness to participate A history of alcohol or drug abuse within the last 2 years Foot ulcer with the etiology from vasculitis, pyoderma gangrenosum, angiodermatitis necroticans (hypertensive ulcer), necrobiosis lipoidica, hydrostatic pressure/venous insufficiency or any neoplasms (basalioma, kaposis sarcoma, squamous cell carcinoma etc) History of drug-induced hepatitis or previous liver enzyme elevations (> 3 times the upper limit of normal) while taking statins History of drug-induced creatine phosphokinase (CPK) > 3 times the upper limit of normal Critical limb ischemia that requires re-vascularisation procedures within 2 months Brachial-ankle index < 0.5 Other serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the trial Any clinically significant abnormality identified in the enrolment medical history, physical examination, laboratory test which, in the judgement of the investigator, would preclude safe completion of the study
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Foot Ulcer years of age or older Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted) Diagnosed Type 2 diabetic (i.e. not juvenile onset) Have a DFU on the plantar surface of either foot Have a DFU of >4 wks but <6 months duration Willing and capable of cooperating to the extent and degree required by the study protocol  Be < 1cm2 or >10cm2 in area, by planimetry Demonstrate overt signs of infection Be located on the dorsal, lateral, or posterior heel area of the foot (Change 2, Amendment 1) Have visible exposed bone or tendon Have an adjacent thermal injury or wound of an etiology other than diabetes Be within 5 cm of any other wound, regardless of etiology Have received enzymatic debriding agents in the past 7 days Have received topical antibiotic therapy in the past 7 days Be less than 1 cm2 or exceed 10cm2 in area by planimetry, after debridement Have exposed bone or tendon, after debridement
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pressure Ulcers Bacteremia Patient in the complex nursing department With contaminated pressure ulcers Going to have a debridement procedure  Penicillin sensitivity Bacteremia that does not react to the antibiotic treatment
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diabetic Polyneuropathy Diabetic Foot Ulcer Diabetes Foot Infection diagnosis of diabetes by WHO ability to provide informed consent 80 years of age  patients with open ulcers or open amputation sites active Charcot arthropathy severe peripheral vascular disease active foot infection dementia -impaired cognitive function- history of drug or alcohol abuse within one year of the study other conditions based on the PI’s clinical judgment
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Neuropathic Foot Ulceration in Individuals With Diabetes confirmed diabetes neuropathic ulcer grade 1/2 (wagner scale) confirmed sensory neuropathy  osteomyelitis patients unable to walk life threatening co-morbidity ankle/brachial index , 0.4
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diabetes Clinical diagnosis of Type 1 or 2 Diabetes most recent A1C greater than or equal to 7.0% Referred to the Diabetes Improvement Program for diabetes care Age 18-80 English Speaking  Patients with corrected visual Acuity >20/50 using a Rosenbaum Pocket Vision Screener, or Patients with a diagnosis of significant dementia, psychosis, or blindness
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Foot Ulcer Patient is greater than 18 years of age Patient has Type I or Type II Diabetes Patient must be able to understand English (self or translator) and give written, informed consent Patient has a plantar forefoot ulcer(s) beneath metatarsal head or toe ulcer which has been present for at least 4 weeks, and has received best practice care Evidence of adequate arterial perfusion: Toe plethysmography reading of mmHg or Transcutaneous oxygen measurement of ≥ 30mmHg Patient is appropriately offloaded (contact cast, pneumatic walking cast) Infection and/or osteomyelitis have been ruled out or are being treated Patients must have a platelet count greater than150,000/mm3 Orthopedic assessment has been completed to rule out mechanical source of ulceration  TcPO2 <30 mmHg and/or toe plethysmography readings of less then 45 mmHg Limb ischemia requiring re-vascularization or impending amputation Untreated wound infection or osteomyelitis Bleeding disorders, hemophilia, sickle cell disease, thrombocytopenia,and leukemia or blood dyscrasias Anemia with hemoglobin level less than 100 g/L will be included as criteria Patient is taking immunosuppressive agents (e.g. corticosteroids, chemotherapeutic agents, transplant medications) Current treatment for malignancy or neoplastic disease or collagen vascular disease Patient has a highly communicable disease or diseases that may limit follow up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis) Patients taking anticoagulants like heparin or coumadin or others which may hinder in clot (thrombin) formation
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Colitis, Ulcerative Active ulcerative colitis, CAI greater than or equal to 4  Antibiotics in the last 3 months Probiotics Alteration to medications in last 3 months
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 12.0-16.0,  Type 1 Diabetes Mellitus Age of adolescent 12-<17 years Type 1 diabetes for >2 years Living in a home environment English reading ability at 5th grade level or above Established diabetes care at participating site Working telephone service Intent to remain living in same region for next 18 months -  Presence of another chronic systemic disease Inpatient psychiatric treatment of patient or caregiver in prior 6 months Current outpatient treatment of psychosis, major depression or substance use disorder in parent/caregiver
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Foot Ulcer, Diabetic Diabetic Angiopathies age over 18 years type I or II diabetes mellitus diagnosed (ADA 1998) for more than 3 years presence of at least one cutaneous ulcer distal to the knee, not involving deep tissues (stages I and II of Wagner’s classification ) and existing for at least three months giving their written informed consent  hypersensibility to heparin or pig derivatives body weight lower than 35 kg presence of clinical signs of infection that did not resolve in spite of oral antibiotics anticoagulant therapy severe impairment of renal or hepatic function bleeding disorder active peptic ulcer arterial hypertension with poor control pregnancy or lactation terminal illness or a prognosis of survival under three months
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  End Stage Renal Disease Hemodialysis Adults, end stage renal disease treated by hemodialysis, patent hemodialysis vascular access (graft or fistula)  Temporary catheter dialysis access, inability to be compliant with study medication
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Venous Ulcer Patients of any race and are between 18 and 90 years of age Patients that are able to understand and are willing to give written informed consent Patients that have a non-healing open venous ulcer for at least one month Patients that have greater than 50% of the ulcers surface area covered with non-viable tissue such as fibrin slough, dry crust or a combination of both Patients that have the clinical signs and symptoms of venous ulceration such as varicosities, hyper pigmentation, stasis dermatitis, lipodermatosclerosis, and edema Patients that have a venous ulcer with a surface area of greater than or equal to 1.5 cm2 Patients that have an ankle to brachial index (ABI) > 0.70  Study wound (target ulcer) etiology is other than venous insufficiency Patient has peripheral arterial disease as determined by the following Ankle/Brachial Index < 0.7 (ulcerated leg), evidence of intermittent claudication Patient has the presence of any of the following in the area of the ulcer: cellulitis, osteomyelitis, and ulcer with exposed bone, tendon or fascia Patient has a known hypersensitivity to dressing components Patient is receiving corticosteroids, immunosuppressive agents, radiation therapy, or chemotherapy where in the investigator’s opinion could interfere with wound healing  Patient is known to have uncontrolled diabetes mellitus (as defined by the investigator) Patient is known to have immunodeficiency disorders that interfere with wound healing Patient has a history of sickle cell anemia, thalassemia, vasculitis, rheumatoid arthritis, lupus erythematosus, polyarteritis nodosa, scleroderma or any connective tissue or collagen vascular disorder Patient has wounds that have been treated with an investigational product within the past thirty days Patient has not signed the informed consent
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Type 2 Diabetes Clinical diagnosis of Type 2 Diabetes most recent A1C >= 7.5% Referred to the Diabetes Care Program for diabetes care Age 18-85; 5. English Speaking  Patients with corrected visual Acuity >20/50 using a Rosenbaum Pocket Vision Screener Patients with a diagnosis of significant dementia, psychosis, or blindness
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 45.0-69.0,  Diabetic Foot Ulcer A diabetic foot ulcer corresponding to grade 2 No history of deep venous thrombosis and no hemorrhage in ulcer  Significant loss of protective sensation Hemorrhage during treatment Vertigo No completion of treatment
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diabetic Foot diabetic ulcer of primarily neuropathic origin on the plantar region of the forefoot ulcer extending through the dermis but without sinus tract, tendon, capsule or bone exposure ulcer present for at least 2 weeks and measuring 1 cm2 diminished sensesation on target extremity/foot ulcer is not infected Type 1 or 2 diabetes with adequate glycemic control Adequate vascular supply to the target extremity  Charcot foot Non-neuropathic ulcers Skin cancer within or adjacent to the target ulcer Osteomyelitis or an infected ulcer Clinically significant medical condition that would impair wound healing Females who are pregnant Received within 4 weeks of study entry systemic corticosteriods, immunosuppresive agents, radiation therapy or chemotherapy
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Keloid Male or females, in good health, and at least 12 years of age Individuals with 2 or more keloids on the trunk, arm, leg, and neck between 0.5 and 2 cm in length Individuals who are willing and able to participate in the requirements of the study, including signing the informed consent In the opinion of the investigator, the 2 keloids can be excised in a similar manner and closed properly with the two techniques and will benefit from the procedure In the opinion of the investigator, the keloid could benefit from surgical procedure  Individuals with keloids that do not fit into the criteria Individuals who are planning pregnancy, pregnant, or breast feeding Individuals with a history of medical or dermatologic conditions which, in the opinion of the investigator, would put the subject at heightened risk or would limit complicate the study evaluations required by the protocol Individuals who present with excessive body hair in the designed keloid area Individuals with uncontrolled diabetes Individuals with autoimmune disorders (HIV/AIDs, SLE) Subjects who have received keloid treatment within one month of the first day of the study Individuals who plan to receive keloid treatment(s) during the study Individuals who are currently taking prescription or over the counter medication or interventions on a regular basis that as part of their mechanism of action, have the potential to mask an inflammatory reaction. Examples of such medications but are not limited to, corticosteroids, non-steroid anti-inflammatory drugs (NSAIDs), antihistamines, aspirin (81mg or less daily dosage permissible), or other medications that in the opinion of the investigator or designee may expose the subject to heightened risk or complicate the study assessments
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 10.0-16.0,  Type 1 Diabetes a current hemoglobin A1c(HbA1c) of >8.0% an average HbA1c of >8.0% during the past year diagnosed with Type 1 diabetes for at least one year reside in the metro Detroit tri-county area  severe mental impairment/thought disorder non-English speaking patient/parent co-morbid major medical condition such as cystic fibrosis